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Abstract. Extracellular matrix (ECM) accumulation in the glo-
merular mesangium is a characteristic feature of diabetic ne-
phropathy. While transforming growth factor-1 (TGF-1) is
the final mediator of ECM accumulation, reactive oxygen
species (ROS) and protein kinase C (PKC) are the upstream
signaling molecules that mediate hyperglycemia-induced ECM
expansion. Magnesium lithospermate B (LAB) is an active
component isolated from Salvia miltiorrhizae with known
renoprotective properties due to its antioxidative effects. Thus,
the present study examined the effects of LAB on renal injury
in streptozotocin-induced diabetic rats (STZR) and on the
activation of mesangial cells cultured under high glucose con-
ditions. Ten micrtograms of LAB/kg per day was started 8 wk
after streptozotocin injection and continued for a period of 8
wk. It significantly suppressed renal malondialdehyde (MDA),
microalbuminuria, glomerular hypertrophy, mesangial expan-
sion, and the upregulation of renal TGF-1, fibronectin, and
collagen in STZR without significantly affecting plasma glu-
cose. Both 30 mM of glucose and 100 uM of H2O2 signifi-
cantly increased TGF-1 and fibronectin protein secretion by
mesangial cells. LAB at 10 g/ml inhibited high glucose- and
H2O2-induced TGF-1 and fibronectin secretion. LAB also
inhibited glucose-induced intracellular ROS generation and
PKC activation in mesangial cells, but it did not directly inhibit
PKC activity at dosages that inhibited ROS generation. The in
vitro data of this study show that LAB inhibits ROS generation
leading to PKC activation and TGF-1 and fibronectin upregu-
lation in mesangial cells cultured under high glucose condi-
tions. Moreover, delayed treatment with LAB was found to
significantly suppress the progression of renal injury in STZR.
LAB may become a new therapeutic agent for the treatment of
diabetic nephropathy.
Diabetic nephropathy is characterized functionally by glomer-
ular hyperfiltration and albuminuria and histologically by the
expansion of the glomerular mesangium, which is related to the
loss of renal function (1).
High glucose (30 mM) is the main determinant of diabetic
nephropathy in both type 1 (2) and type 2 (3) diabetes. Though
transforming factor-1 (TGF-1) is the final mediator of ex-
tracellular matrix (ECM) expansion in diabetic nephropathy
(4–6), increased reactive oxygen species (ROS) generation
(7,8) and protein kinase C (PKC) activation (9,10) in associa-
tion with increased glucose metabolism are considered to be
the main upstream signaling molecules of glucose-induced
vascular injury, which includes diabetic nephropathy.
ROS generation (8,11,12) and PKC activation (13–15) are
elevated in mesangial cells cultured under high glucose con-
ditions. The kidneys of experimental diabetic animals also
exhibit increased lipid peroxidation (16), which is a marker of
increased ROS generation, and PKC activation (16). In addi-
tion, exogenously administered ROS (8,17) and PKC activator
(8) lead to TGF-1 and ECM upregulation in mesangial cells.
Moreover, antioxidants (18–26) and PKC inhibition (27,28)
have been reported to prevent or attenuate both glucose-in-
duced mesangial cell activation and renal injury in diabetes.
Salvia miltiorrhizae radix is a Chinese herbal medicine that
has been traditionally used for the treatment of diabetic com-
plications. Lithospermate B (LAB) was recently isolated from
S. miltiorrhizae and found to have beneficial effects on the
renal function of nephrectomized rats (29), possibly by reduc-
ing ROS generation (30). It is tetramer of caffeic acid (Figure
1). Thus, the present study was undertaken to examine the
effects of delayed LAB treatment on the renal function of
streptozotocin-induced diabetic rats (STZR) and to evaluate the
role of the antioxidative effects of LAB on protection against
diabetic renal injury using mesangial cells cultured under high
glucose conditions.
Materials and Methods
All chemicals and tissue culture plates were obtained from the
Sigma Chemical Company (St. Louis, MO) and Nalge Nunc Interna-
tional (Naperville, IL), respectively, unless otherwise stated.
Received May 15, 2002. Accepted November 22, 2002.
Correspondence to Dr. Hyun Chul Lee and Dr. Young Dong Cho, Department
of Internal Medicine, and Department of Biochemistry, Yonsei University, 134
Shinchon-Dong, Seodaemoon-Ku, P.O. Box 120-749, Seoul, Korea. Phone:
822-361-5425; Fax: 822-393-6884; E-mail: endohclee@yumc.yonsei.ac.kr
1046-6673/1403-0709
Journal of the American Society of Nephrology
Copyright © 2003 by the American Society of Nephrology
DOI: 10.1097/01.ASN.0000051660.82593.19
J Am Soc Nephrol 14: 709–720, 2003
Isolation and Purification of Lithospermate B (LAB)
Magnesium LAB was isolated from S. miltiorrhizae as described
previously (31).
Induction of Experimental Diabetes Mellitus
Male, 10-wk-old, Sprague-Dawley rats were obtained from the
animal facility of Yonsei University College of Medicine, Seoul,
Korea. The animals were housed 2 to 3 per cage in an animal room
controlled at 23  2°C and 55  5% room humidity, under a 12
h-light 12 h-dark cycle. All rats were maintained on standard rat chow
(Samyang rat chow, Seoul, Korea) and tap water ad libitum.
Diabetes was induced by injecting 60 mg/kg of streptozotocin
(STZ) intravenously (dissolved in pH 4.5 citrate buffer immediately
before injection) into the tail vein, as described previously (21).
Control rats (CR: 10 rats) received the same volume of citrate buffer
(2.5 ml/kg). Induction of the diabetic state was confirmed by deter-
mining plasma glucose with commercial enzymatic test strips (Sur-
eStep, LIFESCAN INC.) two days after the streptozotocin injection.
A total of 16 rats with plasma glucose concentrations  300 mg/dl
were defined as diabetic rats. Separate groups of streptozotocin-
induced diabetic rats (STZR) and CR were treated with LAB starting
8 wk after the streptozotocin or citrate buffer treatment. LAB was
orally administered daily at a dose of 10 mg/kg for an additional 8 wk.
The effects of different concentrations of LAB (1 to 20 mg/kg/d) on
albuminuria in diabetic STZR were compared during our preliminary
study. LAB at dose 10 mg/kg per d exhibited better effect than 1
mg/kg per d but similar effect as 20 mg/kg per d, 10 mg/kg per d was
used in further studies. All STZR were survived without insulin
treatment in the present study. We did not administer insulin to avoid
non-metabolic effects of insulin.
Cell cultures
Murine mesangial cells obtained from the American Type Cell
Collection (ATCC: MES-13, cloned from mice transgenic for the
early region of the SV-40 virus, passage 25) were grown in DMEM
containing 5% fetal bovine serum (FBS), 1% streptomycin-penicillin
mixture, 0.5 g/ml fungizone, 44 mM NaHCO3, and 14 mM HEPES
in an atmosphere of 5% CO2 and 95% air at 37°C in a humidified
incubator. Results from MES-13 were confirmed by primary rat
mesangial cell isolated and cultured as described previously (32).
Subcultures were prepared from confluent cultures by trypsinization
in Hanks’ balanced salt solution containing 0.5 mM EDTA and 0.25%
trypsin. These mesangial cells were then grown in DMEM containing
5% FBS to near confluence (80%), and further incubated in serum-
free medium for 24 h to arrest and synchronize cell growth. The
medium was then changed to serum-free DMEM containing different
concentrations of glucose or H2O2 in the presence or absence of LAB.
Treatment with LAB up to 40 g/ml did not show any discernable
cytotoxicity, as estimated by the MTT (3-[4,5-Dimethylthiazol-2-yl]-
2,5-diphenyl-tetrazolium bromide) assay (control: 100  7.6%; 40
g/ml LAB treatment: 92.3 9.1%) and LDH release (control: 9.9
2.4%; 40 g/ml LAB treatment: 12.5  4.9%). Cells were stimulated
for 1 h to determine ROS generation or for 48 h for PKC activity and
TGF-1 and fibronectin protein secretion. We previously demon-
strated that the secretion of TGF-1 and fibronectin protein by mes-
angial cells is significantly increased 48 h after the addition of 30 mM
glucose (32). After incubation, the media were collected, aliquoted,
and frozen at 70°C until required for TGF-1 and fibronectin
protein determinations. Cellular protein concentrations in cell lysates
were measured by the Bio-Rad assay using the Bradford method (33).
Measurement of Urinary Albumin
Urine samples collected over a 24-h period for three consecutive
days were centrifuged at 3000  g for 10 min, and urinary albumin in
the supernatants was determined by ELISA using a Nephrat mi-
croalbumin assay kit (Exocell Inc.). All samples were assayed in
triplicate and the mean value from a given rat was calculated.
Measurement of Malondialdehyde (MDA) in the Renal
Cortex
A modification of the thiobarbituric acid method of Ohkawa et al.
(34) was used to measure the level of lipid peroxidation, as described
previously (35). The renal cortex was excised and homogenized with
extraction solution (iNtron, Seoul, Korea). Aliquots of homogenates
(80 l) were mixed with 80 l of 8% SDS and a reaction mixture
consisting of 120 l of 0.8% 2-thiobarbituric acid and 120 l of 20%
acetic acid. This solution was placed in a water bath and kept at 95°C
for 60 min. After stopping the reaction by cooling with tap water, the
mixture was centrifuged at 15,000  g for 5 min to precipitate
interfering particulate materials. The amount of MDA formed was
determined by spectrofluorometry (SPF-500C, SLM Instruments) at
an emission wavelength of 553 nm at an excitation wavelength of 515
nm and calculated using a tetraethoxypropane standard curve.
Glomerular Histology and Morphometry
For each rat, quantitative morphometry analyses of the different
glomerular domains were performed as described previously (36). A
3-m-thick section was obtained from kidney transversely cut
through the hilus in each rat. On this section, 30 different superficial
glomeruli were randomly sampled for morphometric analysis as fol-
lows: The microscopic slide was scanned clockwise along the super-
ficial cortex, and one glomerulus out of three was analyzed. For every
investigated glomerulus, the following measurements were obtained
with an automated image analysis system: (1) the total glomerular
profile area limited; (2) the glomerular tuft area; (3) the mesangial
matrix area (36).
Immunohistochemical Staining for TGF-1 and
Fibronectin in Renal Cortex
TGF-1 and fibronectin were immunolocalized as described pre-
viously (37). Fifty-micrometer-thick Vibratome sections taken
through the entire kidney were mounted in Epon between polyethy-
lene vinyl sheets. Sections from the cortex were excised and glued on
blocks of Epon, and 3-m sections were cut for light microscopy.
Vibratome sections were washed with 50 mM NH4Cl in PBS three
times for 15 min; before incubation with the primary antibody, the
sections were incubated for 3 h with PBS that contained 1% bovine
Figure 1. Structural formula of lithospermate B (LAB).
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serum albumin, 0.05% saponin, and 0.2% gelatin (solution A). The
tissue sections then were incubated overnight at 4°C with polyclonal
antibody against TGF-1 and fibronectin obtained from Santa Cruz
(Delaware, CA). Antibodies were diluted 1:1000 for TGF-1 and
fibronectin in PBS containing 1% bovine serum albumin (solution B).
After several washes in solution A, the sections were incubated for 2 h
in peroxidase-conjugated goat anti-rabbit and anti-mouse IgG Fab
fragment (Jackson ImmunoResearch Laboratories) diluted 1:100 in
solution B. The sections were then rinsed in solution A and subse-
quently in 0.05 M Trisbuffer (pH 7.6). To detect horseradish perox-
idase, the sections were incubated in 0.1% 3,3'-diaminobenzidine in
0.05 M Tris buffer for 5 min. H2O2 was then added to a final
concentration of 0.01%, and the incubation continued for 10 min.
After washing with 0.05 M Tris buffer three times, the sections were
dehydrated in a graded series of ethanol, embedded in Epon, and
photographed under an Olympus photomicroscope (Tokyo, Japan)
that was equipped with differential interference contrast optics.
Analysis of the percentage of area occupied by TGF-1, and
fibronectin positive staining was performed using computer-assisted
image analysis software (Meta Morph, version 4.6, Universal Imaging
Corporation). For each kidney, more than 30 glomerular profiles, cut
in equatorial section planes and successively appearing in the visual
field of the microscope, were examined.
Staining for Collagen Protein in Renal Cortex: Masson
Trichrome Stain
Paraffin-embedded sections were stained with Masson Trichrome
for collagen. Extent of collagen accumulation was analyzed using
Meta Morph software as described in above.
Assay for TGF-1 Protein: ELISA
The TGF-1 in the renal cortex homogenate and in culture media
supernatant were converted to the active form by HCl treatment (final
concentration, 0.2 M) for 30 min at room temperature followed by
neutralization with equimolar NaOH. The amount of TGF-1 was
Table 1. General characteristics and the effects of LAB in STZ-induced diabetic ratsa
CR
n  5
LABCR
n  5
STZR
n  8
LABSTZR
n  8
Plasma glucose (mg/dl)—8 wk 99 9 97  10 493 77b 462 85b
Plasma glucose (mg/dl)—16 wk 97 9 101 8 519 82b 521 97b
Urine volume (ml/24 h) 20 4 20  1 202 79b 203 41b
Kidney weight (g) 2.25 0.13 2.30 0.20 2.35 0.90 2.04 0.23c
Kidney weight/100 g body weight 0.39 0.02 0.39 0.03 0.76 0.14b 0.69 0.08bc
Glomerular volume (106 3) 1.50 0.36 1.46 0.31 1.72 0.40b 1.44 0.29c
a Values are means  SD. CR, citrate buffer injected age-matched control rats; LABCR, control rats treated with LAB 10 mg/kg per
day; STZR, streptozotocin (60 mg/kg intravenously)—induced diabetic rats; LABSTZR, streptozotocin-induced diabetic rats treated with
LAB 10 mg/kg per day.
b P  0.05 compared with CR.
c P  0.05 compared with STZR.
Figure 2. Effects of LAB on body weight of streptozotocin (STZ)-
induced diabetic rats. Values are means  SD. CR; control rats,
LABCR; control rats treated with LAB 10 mg/kg per d, STZR;
streptozotocin-induced diabetic rats, LABSTZR; streptozotocin in-
duced diabetic rats treated with LAB 10 mg/kg per d. * P  0.05
compared with CR.
Figure 3. Effect of LAB on urinary albumin excretion in streptozo-
tocin-induced diabetic rats. Numbers in parentheses are number of
rats. Urinary albumin was measured by ELISA, as described in
Materials and Methods. * P  0.05 compared with corresponding
normal control rats at 16 wk, † P  0.05 compared with correspond-
ing diabetic rats at either 8 or 16 wk. CR; control rats, LABCR;
control rats treated with LAB 10 mg/kg per d, STZR; streptozotocin-
induced diabetic rats, LABSTZR; streptozotocin induced diabetic
rats treated with LAB 10 mg/kg per d. Values are means  SD.
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determined by quantitative sandwich enzyme immunoassay using the
TGF-1 Emax ImmunoAssay System (Promega) according to the
manufacturer’s description. This TGF-1 Emax ImmunoAssay System
has a detection limit of 32 pg/ml for TGF-1.
Assay for Fibronectin Protein: Western Blot Analysis
Immunoblot analysis was used to determine fibronectin in the renal
cortex homogenate and in the culture media supernatant as described
previously (32). In brief, aliquots of the renal cortex homogenate and
conditioned media were mixed with sample buffer containing SDS
and -mercaptoethanol and heated at 95°C for 15 min. Respective
samples were then applied to a 5% polyacrylamide gel and subjected
to electrophoresis. A prestained SDS-PAGE standard (broad range,
Bio-Rad) was used as a molecular weight marker. The proteins were
transferred onto a nitrocellulose membrane using a transblot chamber
with Tris buffer, and the membranes incubated with rabbit anti-human
fibronectin (HRP-conjugated, DAKO, Glostrup, Denmark) diluted
1:10000 in PBS containing 1% bovine serum albumin for 2 h at room
temperature and subjected to ECL western blotting (Amersham Life
Science, Little Chalfont, UK). Positive immunoreactive bands were
quantified densitometrically and compared with the controls.
Assay for Intracellular ROS
Intracellular ROS production was measured using the method of
Bass et al. (38) modified for confocal microscopy as described pre-
viously (12). In brief, coverglasses of confluent cells obtained 1 h
after high glucose stimulation were washed with Dulbecco’s PBS and
incubated in the dark for 5 min in Krebs-Ringer solution containing 5
mM of 5-(and-6)-chloromethyl-2',7'-dichlorodihydrofluorescein diac-
etate (CM-H2DCFDA, Molecular Probes Inc). CM-H2DCFDA is a
nonpolar compound that readily diffuses into cells, where it is hydro-
lyzed to the nonfluorescent polar derivative 2'7'-dichlorofluorescin
(DCF). Culture dishes were transferred to a Leica DM IRB/E inverted
microscope, equipped with a 20 Fluotar objective and a Leica TCS
NT confocal attachment, and ROS generation was detected (excita-
tion, 488 nm; emission, 515 to 540 nm). The effect of DCFH pho-
toxidation was minimized by collecting the fluorescence image with a
single rapid scan (line average, 4; total scan time, 5.2 s), and identical
Figure 4. Effects of LAB on renal TGF-1 (A), fibronectin (B), and collagen (C) protein expression in streptozotocin-induced diabetic rats.
Immunohistochemical staining for TGF-1 (A) and fibronectin (B) and Masson trichrome staining for collagen (C) were performed after 8 wk
of LAB treatment, as described in Materials and Methods. 1, control; 2, control rats treated with LAB 10 mg/kg per d; 3, streptozotocine-
induced diabetic rats; 4, streptozotocine-induced diabetic rats treated with LAB at 10 mg/kg per day. Magnification, 400.
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parameters, such as contrast and brightness, were used for all deter-
minations. Cells were imaged by differential interface contrast
microscopy.
Assay for PKC activity
Membrane and cytosolic fractions were obtained by the method
described by Kikkawa et al. (13). PKC activities were measured using
a Pep Tag Non-Radioactive Assay kit (Promega). Fluorescence pep-
tide (D-L-S-R-T-L-S-V-A-A-K), which is highly specific for PKC,
was used as a substrate. The phosphorylation of this specific substrate
by PKC alters the peptide’s net charge from 1 to -1. The phosphor-
ylated substrate so obtained was separated in agarose gel at pH 8.0,
and negatively charged bands from the gel were removed and heated
at 95°C until the gel slice melted. Absorbance of the solubilized slice
was measured using a spectrophotometer at 570 nm.
To investigate whether LAB acts as a direct inhibitor of PKC, LAB
(5 to 200 g/ml) was added directly to reaction mixtures containing
rat brain PKC supplied by manufacturer or membrane fractions of
mouse mesangial cell cultured under high glucose for 48 h.
Statistical Analysis
All results are expressed as means  SD. ANOVA was used to
assess the intergroup differences. If the F statistics proved to be
significant, the mean values obtained from each group were compared
using Fisher least significant difference method. A P value of less than
0.05 was used as the criterion for statistically significant difference.
Results
Effects of LAB on the Renal Function of STZR
Rats with plasma glucose concentrations of more than 300
mg/dl at 2 d after STZ injection were used for the present
study. As summarized in Table 1 and Figure 2, STZR failed to
gain body weight compared with the control rats (CR) and
exhibited polyuria. The absolute mean kidney weight of STZR
was similar to the CR. However, mean kidney weight of the
STZR expresed as a function of body weight was significantly
higher than that of CR. STZR also exhibits glomerular hyper-
trophy. Urinary albumin excretion was found to be signifi-
cantly increased 8 wk after STZ injection and continuously
increased up to 16 wk after STZ injection (Figure 3).
The administration of LAB at 10 mg/kg per d did not affect
plasma glucose levels in either the control or the diabetic rats.
Although the mean body weight of LABSTZR was slightly
lower than that of STZR, the difference was not statistically
Figure 4. Continued.
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significant (Figure 2). The plasma glucose of LABSTZR was
similar as that of STZR, it is unlike that LAB decreased food
consumption in diabetic rats. LAB used in the present study did
not affect SGOT, SGPT, and survival of diabetic as well as
control rats.
The administration of LAB, started 8 wk after STZ treatment
for 8 wk significantly ameliorated absolute kidney weight,
kidney weight expressed as a function of body weight, glomer-
ular hypertrophy (Table 1), and albuminuria (Figure 3) in
STZR, although kidney weight expressed as a function of body
weight and urinary albumin excretion in LABSTZR re-
mained statistically higher than in CR.
Immunostaining for TGF-1 (Figure 4A) and fibronectin
(Figure 4B) and Masson Trichrome staining for collagen (Fig-
ure 4C) demonstrated that increases in TGF-1, fibronectin,
and collagen deposition in both glomeruli and tubulointersti-
tium of the renal cortex in diabetic STZR. Semiquantitative
analyses for each parameter in the glomeruli and in the tubules
from different experimental group are summarized in Table 2.
Delayed treatment with LAB effectively inhibited all diabetes-
associated TGF-1, fibronectin, and collagen upregulation in
the renal cortex. Upregulation of TGF-1 and fibronectin in
the cortex were confirmed by ELISA and Western blot analy-
sis, respectively (Figure 5, A and B).
Quantitative morphometry performed by automated image
analysis showed a diabetes-related increase in a mesangial
expansion (Table 2). The mesangial area increased by 2.3-fold,
and LAB treatment reversed mesangial expansion (Table 2).
As summarized in Figure 6, MDA was sevenfold higher in
the renal cortex of STZR than in CR at 16 wk after STZ
treatment. MDA in LABSTZR was significantly lower than
in STZR but statistically higher than in CR and LABCR.
Effects of LAB on TGF-1 and Fibronectin Protein
Secretion by Mesangial Cells Cultured under High
Glucose or H2O2
Quantitative analyses of TGF-1 showed that the exposure
of mesangial cells to 30 mM glucose (Figure 7A) or 100 M
H2O2 (Figure 7B) significantly induced TGF-1 protein secre-
tion after 48 h. LAB inhibited high glucose-induced TGF-1
Figure 4. Continued.
714 Journal of the American Society of Nephrology J Am Soc Nephrol 14: 709–720, 2003
secretion by mesangial cells in a dose-dependent manner (Fig-
ure 7A). LAB at above 20 g/ml decreased TGF-1 protein
secretion by mesangial cells cultured in control 5.6 mM glu-
cose (data not shown), 10 g/ml of LAB was used to determine
the effects on H2O2-induced TGF-1 secretion (Figure 7B).
The effects of LAB on high glucose- or H2O2-induced
fibronectin secretion were qualitatively similar to the changes
observed in TGF-1 secretion. Exposure of mesangial cells to
30 mM glucose (Figure 8A) or 100 M H2O2 (Figure 8B)
significantly increased fibronectin secretion after 48 h. LAB at
10 g/ml inhibited both high glucose- and H2O2-induced, but
not basal, fibronectin secretions by mesangial cells.
LAB also inhibited high glucose-induced fibronectin up-
regulation in primary rat mesangial cells. Fibronectin secretion
under control, 30 mM glucose, and 30 mM glucose in the
presence of 10 g/ml LAB were 100, 161  15 (P  0.05
Table 2. Morphometric studies for kidney cortex (% of positive area)a
CR
n  5
LABCR
n  5
STZR
n  5
LABSTZR
n  5
Glomerular TGF-1 1.69 0.75 1.34 1.12 10.33 4.36b 2.73 1.33bc
Tubulointerstitial TGF-1 0.92 0.41 0.82 0.49 3.15 1.25b 0.93 0.74c
Glomerular fibronectin 1.43 0.92 1.35 0.92 9.99 5.15b 2.37 1.42c
Tubulointerstitial fibronectin 0.72 0.46 0.68 0.61 3.02 1.46b 0.98 0.81c
Glomerular collagen 3.09 1.84 3.19 1.45 11.67 3.62b 3.16 1.50c
Tubulointerstitial collagen 1.32 0.52 1.54 0.52 6.25 2.20b 1.98 0.72bc
Mesangial matrix fraction (%) 8.1 3.4 9.6  3.5 18.8 4.7b 14.1 5.2c
a Values are means  SD. CR, citrate buffer injected age-matched control rats; LABCR, control rats treated with LAB 10 mg/kg per day;
STZR, streptozotocin (60 mg/kg intravenously)—induced diabetic rats; LABSTZR, streptozotocin-induced diabetic rats treated with LAB 10
mg/kg per day. Semiquantitative analysis for area stained for TGF-1, fibronectin, and collagen were performed as described in the method.
b P  0.05 compared with CR.
c P  0.05 compared to STZR.
Figure 5. Effects of LAB on renal TGF-1 and fibronectin protein
expression in streptozotocin-induced diabetic rats. ELISA for TGF-1
(A) and Western blot for fibronectin (B) were performed after 8 wk of
LAB treatment, as described in Materials and Methods. Numbers in
parentheses are number of rats. * P 0.05 compared with normal control
rat; † P 0.05 compared with diabetic rats. CR, control rats; LABCR,
control rats treated with LAB 10 mg/kg per d; STZR, streptozotocin-
induced diabetic rats; LABSTZR, streptozotocin induced diabetic rats
treated with LAB 10 mg/kg per d. Values are means  SD.
Figure 6. Effect of LAB on malondialehhyde (MDA) in the renal
cortex of streptozotocin-induced diabetic rats. Values are means 
SD. * P  0.05 compared with normal control; † P  0.05 compared
with diabetic rats. CR, control rats; LABCR, control rats treated
with LAB 10 mg/kg per d; STZR, streptozotocine-induced diabetic
rats; LABSTZR, streptozotocine-induced diabetic rats treated with
LAB at 10 mg/kg per d.
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versus control), and 74  11% (P  0.05 versus 30 mM
glucose), respectively.
Effects of LAB Intracellular ROS in Mesangial Cells
Cultured under High Glucose or H2O2
The incubation of mesangial cells with 30 mM of glucose for
1 h (Figure 9A) or H2O2 for 15 min (Figure 9B) increased
intracellular ROS. Quantitative analyses of ROS showed that
the exposure of mesangial cells to high glucose increased
intracellular ROS 11-fold compared with control and that this
was effectively inhibited by the addition of LAB 10 g/ml; 100
M of H2O2 increased intracellular ROS tenfold compared
with control, and this was also effectively inhibited by the
addition of LAB at 10 g/ml.
Effects of LAB on PKC Activity in Mesangial Cells
Cultured under High Glucose
As shown in Figure 10, 30 mM of glucose did not affect
PKC activity in the cytosolic fraction of mesangial cells but
increased PKC activity in the membrane fraction, suggesting
that high glucose induced PKC activation under our experi-
mental conditions. Increased PKC activity in the membrane
fraction of mesangial cells cultured under 30 mM glucose
condition was inhibited by LAB in a dose-dependent manner
(Figure 10).
LAB also inhibited high glucose-induced membrane PKC
activity upregulation in primary rat mesangial cell. The PKC
activity in control, 30 mM glucose, and 30 mM glucose  10
g/ml LAB were 100, 251 14 (P 0.05 versus control), and
176  27% (P  0.05 versus 30 mM glucose), respectively.
As summarized in Figures 11A and 11B, exogenously ad-
ministered LAB into purified rat brain PKC or membrane
fraction of mouse mesangial cell did not inhibit PKC activity at
concentrations up to 40 g/ml. Concentrations of LAB higher
Figure 7. ELISA for TGF-1 protein secreted by mesangial cells.
Growth arrested and synchronized mesangial cells were grown in differ-
ent concentrations of LAB containing either 5.6 mM of D-glucose 24.4
mM mannitol or 30 mM of D-glucose (A) or in different concentrations
of H2O2 in the presence or absence of LAB (B) for 48 hours. Values
represent means SD obtained from four individual experiments; * P
0.05 compared with 5.6 mM D-glucose 24.4 mM mannitol; † P 0.05
compared with 30 mM D-glucose.
Figure 8. Western blots of fibronectin protein secreted by mesangial
cells. Growth arrested and synchronized mesangial cells were grown
in different concentrations of LAB containing either 5.6 mM D-
glucose  24.4 mM mannitol or 30 mM of D-glucose (A) or in
different concentrations of H2O2 in the presence or absence of LAB
(B). Values represent means  SD obtained from four individual
experiments. * P  0.05 compared with 5.6 mM D-glucose  24.4
mM mannitol control; † P  0.05 compared with 30 mM glucose.
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Figure 9. Effect of LAB on high glucose- (A) and H2O2- (B) induced dichlorofluorescein-sensitive intracellular reactive oxygen species in
mesangial cells. Growth arrested and synchronized quiescent mesangial cells, grown on coverglasses, were incubated in 5.6 mM D-glucose 
24.4 mM mannitol or 30 mM of D-glucose in the presence or in the absence of LAB for 1 h, washed with PBS, and incubated in the dark for
10 min in Krebs-Ringer solution containing 5 mM of 5-(and-6)-chloromethyl-2',7'-dicchlorodihydrofluorescein diacetate (CM-H2DCFDA).
Culture dishes were transferred to a Leica DM IRB/E inverted microscope, equipped with a20 Fluotar objective and a Leica TCS NT confocal
attachment, and ROS generation was visualized. A-1: 5.6 mM D-glucose  24.4 mM mannitol control; A-2: 30 mM glucose; A-3: 30 mM
glucose  5 g/ml LAB; A-4: 30 mM glucose  10 g/ml LAB; A-5: 30 mM glucose  40 g/ml LAB; B-1: 5.6 mM D-glucose; B-2: 5.6
mM glucose  10 M H2O2; B-3: 5.6 mM glucose  10 M H2O2  10 g/ml LAB; B-4: 5.6 mM glucose  100 M H2O2; B-5: 5.6 mM
glucose  100 M H2O2  10 g/ml LAB. Representative data from four individual experiments.
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than 100 g/ml directly inhibited PKC activity in a dose-
dependent manner.
Discussion
The efficacy of antioxidant supplementation when they were
administered at the onset of experimental diabetes has been
reported to prevent diabetic renal injury (19,21–26). The
present study demonstrates that delayed treatment with LAB at
a dose that reduces renal MDA accumulation significantly
suppresses the progression of albuminuria, glomerular hyper-
trophy, mesangial expansion, and upregulation of renal TGF-
1, fibronectin, and collagen expression in STZR. In view of
the fact that in the clinical situation treatment is often initiated
after the onset of diabetic nephropathy, the present finding
suggests that LAB may prove to be a new therapeutic agent for
the treatment of diabetic nephropathy.
Renal TGF-1, fibronectin, and collagen upregulations in
STZR were totally blocked by delayed LAB treatment. The
levels of urinary albumin excretion and MDA in the renal
cortices of LABSTZR were also significantly lower than that
of the STZR but statistically higher than those of CR in the
present study. These differences may have resulted from the
different time courses among TGF-1, fibronectin, and colla-
gen upregulation in the renal cortex, albuminuria, or MDA
accumulation in STZR and/or the sensitivity of each measure-
ment used in present study. The concentration of MDA and the
expression of TGF-1, fibronectin, and collagen in renal cortex
at 8 wk after STZ injection but before treatment with LAB
could not be measured. UAE in diabetic rats in the present
study are similar to those in a previous study (39).
We, therefore, examined the antioxidative property of LAB
by using of mesangial cells cultured under high glucose, an
accepted in vitro model for diabetic nephropathy. LAB inhib-
ited high glucose-induced intracellular ROS, and LAB, at a
dose-inhibiting ROS generation, inhibited both high glucose-
and H2O2-induced TGF-1 and fibronectin protein secretion
by mesangial cells; therefore, the protective effects of LAB on
experimental diabetic nephropathy may be largely due to its
antioxidative effects.
The inhibition of H2O2-induced intracellular DCF-sensitive
fluorescence by LAB (Figure 9B) is in general agreement with
previous reports, which demonstrated that S. miltiorrhizae nor-
malizes catalase activity and restores superoxide dismutase
levels (30). Previous studies have demonstrated that high glu-
cose increases intracellular ROS as a result of glucose uptake
and metabolism in mesangial cells (12) and found that different
Figure 10. Effect of LAB on high glucose-induced PKC activation in
mesangial cells. Growth arrested and synchronized quiescent mesan-
gial cells grown on plates were incubated with 5.6 mM D-glucose 
24.4 mM mannitol or 30 mM of D-glucose in the presence or in the
absence of LAB for 24 h, washed with PBS, and harvested. PKC
activities were measured using a Pep Tag Non-Radioactive Assay kit
for PKC. The fluorescent peptide D-L-S-R-T-L-S-V-A-A-K, which is
highly specific for PKC, was used as a substrate. Values are means 
SD obtained from four individual experiments. * P  0.05 compared
with 5.6 mM D-glucose  24.4 mM mannitol control, †; P  0.05
compared with 30 mM glucose control.
Figure 11. Direct effect of LAB on PKC activity. To investigate
whether LAB acts as a direct inhibitor of PKC, LAB (5 to 400 g/ml)
was added directly to reaction mixtures containing rat brain PKC (A)
or containing membrane fractions of mouse mesangial cell that were
incubated under high glucose conditions for 48 h (B). * P  0.05
compared with control; † P  0.05 compared with high glucose.
Values are means  SD.
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antioxidants ameliorate high glucose-induced TGF-1 and
ECM synthesis in mesangial cells (18,20). In agreement with
these studies, we found that LAB, at concentrations that inhib-
ited high glucose-induced intracellular ROS generation, effec-
tively blocked TGF-1 and fibronectin upregulation in mesan-
gial cells cultured under high glucose conditions.
Although LAB treatment inhibited high glucose-induced
PKC activation in mesangial cells, LAB at concentrations up to
40 g/ml, did not directly inhibit PKC activity. This suggests
that the inhibition of high glucose-induced PKC activation by
LAB may occur indirectly through the inhibition of intracel-
lular ROS generation. PKC activation under hyperglycemic
conditions is largely related to an increase in the de novo
synthesis of diacylglycerol (DAG), the major endogenous ac-
tivator of PKC, and results from an increased glucose metab-
olism (10). However, PKC can be sensitively regulated by
redox modification, which is independent of DAG. The N-
terminal regulatory domain of PKC contains zinc-binding,
cystein-rich motifs that are susceptible to oxidative modifica-
tion, and which are readily oxidized by peroxide. When oxi-
dized, the autoinhibitory function of the regulatory domain is
compromised and cellular PKC activity is consequently stim-
ulated. In addition, H2O2 activates PKC- through the activa-
tion of tyrosine kinase (40). In this context, a recent study by
Nishikawa et al. (7) demonstrated that ROS play an important
role in PKC activation in endothelial cells cultured under high
glucose conditions. PKC activations in mesangial cells cul-
tured under high glucose conditions (20) and in STZ-induced
diabetic rats (41) were effectively inhibited by antioxidants.
Although the chemical structure of LAB is known (Figure
1), it is not clear at present whether mesangial cells take up
LAB. Further studies are needed to determine the exact mech-
anisms involved in inhibition of intracellular ROS by LAB.
Potential toxic effects of LAB should also be investigated in
detail, because the mean body weight of LABSTZR was
slightly lower, although it is not statistically different, than that
of STZR (Figure 2). Data from the present study provided that
LAB did not affect survival, SGOT, and SGPT in diabetic
STZR as well as CR (data not shown).
In conclusion, LAB inhibited the ROS generation, and this
led to PKC activation and TGF-1 and fibronectin upregula-
tion in mesangial cells cultured under high glucose conditions.
Moreover, delayed treatment with LAB significantly sup-
pressed the progression of renal injury in diabetic rats. LAB,
an active component of S. miltiorrhizae radix, may prove to
be a new therapeutic agent for the treatment of diabetic
nephropathy.
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